Gandhar Oil Refinery (India) reports Q1 FY26 consolidated PAT lower at Rs. 26.1 Cr YoY

Gandhar Oil Refinery (India) Q3 FY25 consolidated revenues reaches Rs. 1,005.3 Cr

Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL

Briefs: Gandhar Oil Refinery India, FDC and Apitoria Pharma

FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets

Gandhar Oil posts robust FY26 profit

PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion

Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India

Company to launch product after the expiry of semaglutide patent in India